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One of the most severe complications after successful cancer therapy is the development of therapy-
related myeloid neoplasms (t-MN). Constitutional genetic variation is likely to impact on t-MN risk. We 
aimed to evaluate if polymorphisms in the p53 pathway can be useful for predicting t-MN susceptibility. 
First, an association study revealed that the Pro variant of the TP53 Arg72Pro polymorphism and the 
G allele of the MDM2 SNP309 were associated with t-MN risk. The Arg variant of TP53 is more efficient 
at inducing apoptosis, whereas the Pro variant is a more potent inductor of cell cycle arrest and DNA 
repair. As regards MDM2 SNP309, the G allele is associated with attenuation of the p53 apoptotic 
response. Second, to evaluate the biological effect of the TP53 polymorphism, we established Jurkat 
isogenic cell lines expressing p53Arg or p53Pro. Jurkat p53Arg cells presented higher DNA damage and 
higher apoptotic potential than p53Pro cells, after treatment with chemotherapy agents. Only p53Pro 
cells presented t(15;17) translocation and del(5q). We suggest that failure to repair DNA lesions in 
p53Arg cells would lead them to apoptosis, whereas some p53Pro cells, prone to cell cycle arrest and 
DNA repair, could undergo misrepair, generating chromosomal abnormalities typical of t-MN.
Therapy-related myeloid neoplasms (t-MN) include therapy-related acute myeloid leukemia (t-AML) and 
therapy-related myelodysplastic syndrome (t-MDS), which in most cases will progress to overt AML. They are 
neoplastic hematopoietic disorders occurring as a late complication after chemotherapy and/or radiation therapy 
used to treat other malignancies and are recognized as a distinct entity by the World Health Organization clas-
sification1. T-MN constitute the most frequent secondary neoplasias, and their incidence has risen dramatically 
over the last few years, as both the number of patients receiving cytotoxic agents and the population of long-term 
cancer survivors have increased2. Collected data suggest that up to 20% of patients treated for a primary cancer 
develop t-MN3 with latency periods between diagnosis of the primary disease and occurrence of t-MN ranging 
between several months to several years4. Patients with t-MN are typically resistant to conventional treatment and 
are considered to have an inferior outcome compared with de novo MN5.
Cytotoxic agents, like alkylating agents and topoisomerase II poisons in addition to radiotherapy, are associ-
ated with t-MN. Depending on the therapeutic agent used to treat the primary cancer, two types of t-AML can be 
distinguished. The most common, comprising 75–90% of cases, occurs 5 to 10 years after exposure to alkylating 
agents or radiation, and is frequently accompanied by clonal unbalanced cytogenetic abnormalities, such as the 
loss of part or all of chromosomes 5 or 7 or both4,6. It is preceded frequently by MDS and mutations of the TP53 
tumor suppressor gene are also common7. The less common subtype arises after treatment with drugs targeting 
topoisomerase II. It is characterized by a typical latency of only 1 to 5 years, previous MDS is rare, and it harbors 
balanced rearrangements involving MLL at 11q23 or less often RUNX1 at 21q22 or t(15;17) PML-RARA4,8,9.
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Apart from killing tumoral cells, alkylating agents and topoisomerase II poisons can also induce high levels of 
DNA damage (mainly double strand breaks, DSBs) in rapidly dividing non-tumoral cells, such as hematopoietic 
progenitor cells. These DSBs can be repaired by homologous recombination repair (HRR) or non-homologous 
end joining (NHEJ). However, misrepair of these highly mutagenic lesions can lead to chromosomal alterations 
and genomic instability that can induce leukemic transformation of cells and can ultimately give rise to t-MN, if 
accompanied by inappropriate avoidance of cell death. Otherwise, failure to repair DNA DSB, if DNA damage is 
irreversible, results in an apoptotic response and cell death (reviewed in10). Interestingly, there is evidence of large 
inter-individual variations in DNA repair capacity, which may be due to differences in genetic makeup11. In this 
regard, a good constitutive capacity for DSB repair and/or apoptosis could be crucial for avoiding malignant stem 
cell transformation and leukemogenesis associated with the clinical use of some cytotoxic drugs. Noteworthy, only 
a subset of all patients exposed to genotoxic therapy develop t-MN. Moreover, individuals who develop a t-MN 
are at particularly high risk of developing multiple subsequent cancers12. Overall, these data suggest that genetic 
factors may contribute to t-MN risk. Studying the heritable predisposition to t-MN is of paramount importance, 
since the identification of patients prone to develop it would enable planning treatment protocols designed to 
minimize risk. Not surprisingly, several studies have identified polymorphisms associated with increased t-MN 
susceptibility in a number of genes involved in drug metabolism or DNA repair (reviewed by13). However, most 
of these studies have produced inconclusive results. This might be due in part because many of these works used 
healthy individuals or de novo MN samples as a reference group, instead of patients who had undergone therapy 
for a primary tumor but had not developed t-MN some years later. So far, five studies have used an appropriate 
comparison group14–18 and only two of them observed positive association with candidate genes, particularly 
with genes involved in DNA repair and apoptosis (TP53) and in DNA synthesis/repair (MTHFR)17,18. Ding et al.18  
observed synergistic impact of single nucleotide polymorphisms (SNPs) in TP53 and MTHFR on t-MN after 
Hodgkin lymphoma; however, Guillem et al.17 reported that MTHFR risk haplotype is variable depending on the 
primary neoplasia. Therefore, it seems that TP53 polymorphic variants might be related to a higher risk of t-MN. 
These studies need further replication and extension with functional approaches13.
The p53 protein, when upregulated after genotoxic stress caused by anticancer therapy, for example, induces 
pathways that ultimately lead to either cell cycle arrest and DNA damage repair or apoptosis. Interestingly, the 
TP53 gene harbors a common SNP that results in expression of either arginine (Arg) or proline (Pro) at codon 
72, the Arg72Pro polymorphism. There is experimental evidence in cell models that the Arg variant is signifi-
cantly more efficient at inducing apoptosis, whereas the Pro variant is a more potent inductor of cell cycle arrest 
and DNA repair19–21. Ding et al.18 observed a higher risk for t-MN after lymphoma among Pro carriers of the 
Arg72Pro polymorphism.
Notably, Ellis et al.22 observed that individuals carrying both the TP53 Pro allele and the MDM2 G allele are at 
increased risk of t-AML, although neither polymorphism alone was associated with t-AML. The MDM2 protein 
is an important negative regulator of p53. MDM2 has been shown to inhibit p53 by regulating its nuclear export, 
its capacity as a transcriptional activator and its stability (reviewed in23). It has been observed that a SNP located 
in the core promoter of MDM2 (SNP309, T/G) affects binding of the transcription factor SP1. Particularly, the 
G-allele is bound more efficiently by SP1 than the T-allele, resulting in high levels of MDM2 mRNA and protein, 
and subsequent attenuation of the p53 response24.
In the present study, we wanted to investigate whether polymorphisms in the p53 pathway can be useful for 
predicting t-MN susceptibility. First, we aimed at determining if the Pro variant of Arg72Pro polymorphism at 
TP53 and the G allele at MDM2 SNP309 have an influence on the t-MN risk comparing the genotypes of a series 
of patients with this disease versus an appropriate control group. Moreover, we wanted to compare in a cell-based 
model, after treatment with an alkylating agent (busulfan) or a topoisomerase II poison (doxorubicin), the differ-
ences between the two TP53 polymorphic variants concerning i) the number of DNA DSBs, measured by count-
ing phosphorylated H2AX (γH2AX) foci25, ii) levels of DNA damage, measured as chromosome breaks or sister 
chromatid exchanges (SCEs), iii) the number of apoptotic cells, and finally iv) the development of chromosomal 
abnormalities typical of t-MN after a long term culture.
Results
SNP genotyping of TP53 and MDM2. Forty and 39 t-MN samples were successfully genotyped for 
the TP53 Arg72Pro polymorphism and the MDM2 SNP309, respectively. Regarding controls, 54 samples were 
successfully genotyped for the TP53 Arg72Pro polymorphism and 47 for the MDM2 SNP309. There were 34 
t-MN samples and 35 controls with genotype information for both TP53 and MDM2 genes. Unfortunately, 
not all samples could be genotyped for both genes due to lack of good-quality DNA. Supplementary Table S2 
shows the genotype distribution of both SNPs. TP53 followed the Hardy-Weinberg equilibrium, but not MDM2 
(p = 0.04). The Pro variant of the TP53 Arg72Pro polymorphism was more frequent in the patients with t-MN; 
however, the association was not statistically significant, probably due to the small population size (log-addi-
tive model: OR = 1.69, 95% confidence interval [CI] = 0.90–3.17, p = 0.096; recessive model, Pro/Pro vs. Arg/
Arg + Pro/Arg: OR = 3, 95% CI = 0.70–12.82, p = 0.125). On the other hand, MDM2 SNP309 was highly signifi-
cantly associated with t-MN risk in log-additive model (OR = 2.49, 95% CI = 1.34–4.61, p = 0.002), in dominant 
model (T/G + G/G vs. T/T: OR = 3.75, 95% CI = 1.51–9.31, p = 0.003) and in codominant model (T/G vs. T/T: 
OR = 3.09, 95% CI = 1.14–8.35; G/G vs. T/T: OR = 5.60, 95% CI = 1.58–19.87; p = 0.009). These associations were 
maintained after adjustment by sex. The synergistic effect of both genes was tested and significant association 
was found between TP53 and MDM2 genotypes and risk of t-MN. The TP53 Arg/Arg and MDM2 T/T genotype 
was underrepresented in t-MN patients compared to non-t-MN individuals (6% vs. 29%, p = 0.013, chi-square 
test). Moreover, the only case with the TP53 Pro/Pro and MDM2 G/G genotype had a t-MDS. The TP53 Arg/Arg 
or Pro/Arg and MDM2 T/T genotype was less frequent in t-MN patients compared to non-t-MN individuals 
(18% vs. 40%, p = 0.041, chi-square test), whereas the TP53 Pro/Pro and MDM2 G/G or T/G genotype was more 
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frequent in t-MN patients, even though differences were not statistically significant (9% vs. 0%, p = 0.114, Fisher 
exact test).
Analysis of γ-H2AX foci. We next addressed in vitro whether the two polymorphic variants of TP53 result 
in distinct cellular responses to anticancer drugs in isogenic Jurkat cell lines expressing p53Arg and p53Pro. First, 
γ-H2AX foci kinetics was assessed after drug treatment (Fig. 1A,B, Supplementary Table S3 and Fig. S1). We 
observed foci (>1 foci/cell) after 2.5 h in cells treated with busulfan and after 5 h in cells treated with doxorubicin. 
After foci were detectable, Jurkat p53Arg cells presented a significantly higher number of foci per cell than Jurkat 
p53Pro cells at all times tested and for both treatments, except at 48 h (p values are shown in Supplementary 
Table S3). Maximum values of γ-H2AX foci were detected at 15–20 h post-treatment for Jurkat p53Arg, and at 
5–15 h for Jurkat p53Pro.
Chromosome breakage assay and SCE assay. We evaluated the effect of the TP53 polymorphism 
on the number of breaks on chromosomes (chrb) or chromatids (chtb) in the p53Pro- and p53Arg-expressing 
isogenic cell lines 24 h after drug treatment (Fig. S2). Jurkat p53Arg cells had a statistically significantly higher 
number of chtb (p = 0.016) and total chromosomal aberrations (p = 0.018) than Jurkat p53Pro cells after treat-
ment with busulfan (Fig. 2A). On the other hand, Jurkat p53Arg cells treated with doxorubicin had more chtb 
than Jurkat p53Pro cells but differences were not statistically significant (p = 0.184); moreover, they had a statisti-
cally significantly higher number of chrb (p = 0.012) and total chromosomal aberrations (p = 0.021) than Jurkat 
p53Pro cells (Fig. 2B).
To further investigate the difference in DNA damage induction, we also analyzed the levels of SCE 48 h after 
drug treatment using the same cells (Fig. S3). Consistent with the data from chromosome breakage assay at 24 h, 
SCE assay demonstrated that Jurkat p53Arg cells had more SCE per cell than Jurkat p53Pro cells 48 h after treat-
ment with busulfan (p = 0.02) or doxorubicin (p = 5 × 10−6) (Fig. 2C).
Cell proliferation. We next evaluated whether mitotic and proliferation indexes would also be affected by 
p53Arg or p53Pro expression. Untreated Jurkat p53Arg cells and Jurkat p53Pro cells had a mitotic index of 28.8% 
and 27%, respectively, at 24 h, and 38.1% and 39.6%, respectively, at 48 h. These differences were not statistically 
significant. However, the cells presented differences in their mitotic index after treatment with drugs (Fig. 3A). 
Jurkat p53Arg treated with either busulfan or doxorubicin divided more actively than Jurkat p53Pro both at the 
24-h and 48-h cultures (p < 0.001 in all cases).
Figure 1. Kinetics of γ-H2AX foci formation and disappearance in Jurkat p53Arg and Jurkat p53Pro cells after 
treatment with busulfan (A) or doxorubicin (B) for 2 h. Values correspond to means ± SEM and results are 
representative of two independent experiments.
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Figure 2. DNA damage in Jurkat p53Arg and Jurkat p53Pro cells treated with busulfan or doxorubicin. (A,B) 
Chromosome alterations per cell (chtb, chtg, chrb, chrg, radial chromosomes) in Jurkat p53Arg and p53Pro 
treated with busulfan (A) or doxorubicin (B) for 2 h and cultured for 24 h; (C) Number of SCE per cell after 
treatment with busulfan or doxorubicin for 2 h and culture of 48 h. Data are plotted as means ± SEM and 
results are representative of two independent experiments. Asterisks denote significant differences (*p < 0.05; 
***p < 0.001, Mann-Whitney test).
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The proliferation index for doxorubicin-treated cells was 1.32 ± 0.12 in Jurkat p53Arg cells and 1.18 ± 0.23 in 
Jurkat p53Pro cells, whereas for busulfan-treated cells, it was 1.49 ± 0.15 in Jurkat p53Arg cells and 1.30 ± 0,09 
in Jurkat p53Pro cells. As can be observed in Fig. 3B, Jurkat p53Pro cells presented more cells in mitosis I (MI) 
and fewer cells in MII than p53Arg cells after chemical treatment, suggesting that more cells were arrested at MI.
Apoptosis assay. We next determined whether there were any differences in the apoptosis-induction poten-
tial between the isogenic cells expressing p53Arg or p53Pro (Fig. S4). The results revealed that Jurkat p53Arg 
cells had a consistently higher level of apoptosis than Jurkat p53Pro cells after treatment with either busulfan 
or doxorubicin at all points analyzed, and even with no drug treatment, which corresponds to spontaneous cell 
death (Fig. 4).
FISH analysis and PCR. Then, a FISH analysis and PCR was carried out to evaluate if Jurkat p53Pro cells 
presented some of the chromosomal/molecular abnormalities typical of t-AML after a long-term culture of 100 
days. The analysis showed that either Jurkat p53Arg or Jurkat p53Pro cells did not present the MLL rearrange-
ment after treatment with doxorubicin. Interestingly, Jurkat p53Pro cells had 6.3% and 15.5% of nuclei with 
the t(15;17) PML-RARA translocation after treatment with doxorubicin in the two experiments performed 
(Fig. 5A), whereas Jurkat p53Arg cells did not present the rearrangement. Many hiperdiploid cells were observed 
in the doxorubicin-treated cultures: 52% of metaphases in Jurkat p53Pro cells and 51% in Jurkat p53Arg cells, as 
expected given the implication of topoisomerase II enzyme in sister chromatid separation (reviewed in26). On the 
other hand, either Jurkat p53Arg or Jurkat p53Pro cells did not present deletion of chromosome 7 after treatment 
with busulfan, but Jurkat p53Pro cells had deletion at chromosome 5. Two percent of cells and 26.9% of cells 
presented deletion of 5q33 after treatment with busulfan in the two experiments performed (Fig. 5B), whereas 
Jurkat p53Arg cells did not present the deletion. None of the cell lines presented FLT3-ITD or NPM1 mutations.
Discussion
One of the most severe complications after successful cancer therapy is the development of a secondary cancer, 
mostly an acute leukemia of myeloid lineage (t-MN). Unfortunately, the number of these therapy-related cancers 
has constantly increased over recent decades, because cancer patients are now surviving longer. Constitutional 
genetic variation is likely to impact on an individual’s risk of developing such a secondary cancer. Therefore, the 
Figure 3. Cell proliferation in Jurkat p53Arg and Jurkat p53Pro cells treated with busulfan or doxorubicin for 
2 h. (A) Mitotic index in Jurkat p53Arg and Jurkat p53Pro cells treated with busulfan or doxorubicin for 2 h 
and cultured for 24 h or 48 h; (B) Number of cells at MI, MII, or MIII in Jurkat p53Arg and Jurkat p53Pro cells 
treated with busulfan or doxorubicin for 2 h and cultured for 48 h. Results are representative of two independent 
experiments. Asterisks denote significant differences (***p < 0.001, z-test).
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analysis of genetic polymorphisms may help to identify patients at high risk of developing t-MN, which might 
benefit from surveillance and/or from personalized treatment.
In the present study, we investigated the impact of polymorphisms in the p53 pathway on the development 
of t-MN in a series of 45 t-MN patients and their appropriate controls. We observed that the TP53 Arg72Pro 
polymorphism and the MDM2 SNP309 were associated with t-MN risk. The Pro variant of TP53 and the G allele 
of MDM2 were overrepresented in t-MN patients as compared to non-t-MN individuals. This confirms previous 
results by22 for TP53 and MDM2 and by18 for TP53. It is well known that the two forms of p53 at codon 72 have 
Figure 4. Apoptosis potential of Jurkat p53Arg and Jurkat p53Pro cells after treatment with busulfan (A) or 
doxorubicin (B) for 2 h. Data are plotted as mean ± SEM of three independent experiments. Asterisks denote 
significant differences (*p < 0.05; ***p < 0.001, t-test).
Figure 5. FISH images of nuclei from the Jurkat p53Pro cell line after a 100-day culture using the translocation 
PML-RARA specific probe (A) or the del(5q) specific probe (B). (A) Green signal corresponds to RARA gene 
on chromosome 17, red signal corresponds to PML gene on chromosome 15, fusion signal corresponds to 
translocation t(15;17). (B) Blue signal corresponds to 5p15, red signal corresponds 5q31, and green signal 
corresponds to 5q33. This cell has a deletion of 5q33.
www.nature.com/scientificreports/
7SciEntiFic REPORTS |           (2019) 9:150  | DOI:10.1038/s41598-018-36931-x
differences in their abilities to induce apoptosis and suppress transformed cell growth19. As regards to MDM2 
SNP309, the homozygous G/G or heterozygous T/G genotypes have been shown to be associated with signifi-
cantly higher levels of MDM2 expression in normal and tumoral cells, accompanied by suppression of p53 and 
attenuation of the p53 apoptotic response after exposure to chemotherapy agents (reviewed in23). Moreover, the 
G allele has been linked to increased cancer risk for many human tumors and in mouse models; however, some 
other reports have failed to obtain the same results (reviewed in27).
Overall, the above-mentioned reports and the association study presented here suggest the p53 pathway as 
a likely t-MN risk factor. To analyze this further, we developed a cellular model with isogenic Jurkat cell lines 
expressing the Arg and the Pro variant of the TP53 Arg72Pro polymorphism, in order to see whether the altered 
biochemical and/or biological function of p53 due to polymorphisms can have an effect on cells after treatment 
with chemotherapy agents.
A summary of the results obtained in the cell-based model is shown in Table 1. Regarding γ-H2AX foci, Jurkat 
p53Arg cells presented more foci per cell than Jurkat p53Pro cells after treatment with busulfan or doxorubicin. 
Previous studies have reported that γ-H2AX foci analysis can reflect DSB repair capacity: repair-deficient mouse 
strains and radiosensitive cells/mice present increased foci levels compared to repair-proficient mouse strains and 
radioresistant cells/mice, respectively28–30. This means that if Jurkat p53Pro cells had fewer DSBs, it is probably 
due to the fact that expression of the Pro variant results in a significantly higher DNA-repair capacity than the 
Arg variant, as others have observed21. The Pro variant activates transcription of several p53-dependent target 
genes involved in DNA repair (i.e. GADD45, DDB2, and RRM2B) more efficiently than the Arg form21. Moreover, 
Siddique & Sabapathy21 evaluated the correct NHEJ activity, which rejoins broken DNA ends, and observed that 
the Pro form is more potent than the Arg form in the repair of exogenously damaged plasmids, both in tumoral 
and non-tumoral mouse cells.
Unlike ionizing radiation, most DNA damaging drugs, such as alkylating agents and topoisomerase II poisons, 
do not induce DSBs directly. This explains why maximum values of γ-H2AX foci were observed several hours 
after treatment, as other authors have described31. Very late counts of as many as 20 γ-H2AX foci can correspond 
to cells with unrepaired DSBs or to cells that are likely to die32.
Regarding chromosome and chromatid breaks and SCE per cell, again Jurkat p53Arg cells presented a higher 
level of DNA damage than Jurkat p53Pro cells after drug treatment. Siddique & Sabapathy21 reported that 
Pro-expressing cells exhibit reduced micronuclei formation compared to Arg-expressing cells. Later, Litviakov33 
showed that cancer patients with Pro/Pro genotype have fewer chromatid breaks in comparison to Arg/Pro and 
Arg/Arg carriers. Moreover, chromosomal radiosensitivity, as measured by the G2-chromosome break assay, has 
been reported to be associated with polymorphisms in TP53 codon 7234. In that study, reduced frequencies of 
radiation-induced chromatid aberrations were observed in normal human lymphoblast cell lines with the Pro/
Pro genotype compared to other genotypes.
We observed that chtb was the predominant type of chromosomal aberration, as would be expected for the 
mechanism of action of the two drugs used. Busulfan generates adducts, which cause replication stall during cell 
division, generating DSBs in the replication fork. If not properly repaired, these DSBs result in chtb in mitosis. 
On the other hand, doxorubicin inhibits the ligase activity of topoisomerase II, generating DSBs mostly behind 
the replication fork and near the transcription bubble26. When DSBs are generated behind the replication fork 
or during transcription in G2, and if they are not repaired, they result in chtb in mitosis. When generated during 
transcription in G1, and if breaks in both strands remain unrepaired through S phase, the result will be visible in 
both chromatids as a chrb in next mitosis35.
In relation to cell proliferation, we observed that Jurkat p53Arg cells treated with drugs for 2 h and cultured 
for 24 h and 48 h divided more actively (higher mitotic and proliferation indexes and more MII cells) than Jurkat 
p53Pro cells, even though the mitotic index was low (maximum values were 55% of the untreated cells index). On 
the other hand, more Jurkat p53Pro cells were arrested at MI. It is known that expression of the Pro variant in cell 
lines results in a predominant cell cycle arrest in G136, most likely to allow cells to carry out DNA repair processes.
As for apoptosis, Jurkat p53Arg cells presented higher apoptotic potential than p53Pro cells after treatment 
with busulfan or doxorubicin for 16 h or 24 h. Back in 1999, Thomas et al.19 reported that the two forms of p53 
have differences in their transcriptional activities and in their abilities to induce apoptosis and suppress trans-
formed growth. Several reports published later confirmed that the Arg variant induces apoptosis more efficiently 
than does the Pro variant, probably due to its enhanced localization to the mitochondria37, to its more efficient 
induction of specific apoptosis-associated genes, e.g. NOXA, PUMA, PIGPC1 and AIP136,38, or even to its ability 
Parameter measured Jurkat p53Arg Jurkat p53Pro
Number of foci up to 24 h ↑ ↓
Number of foci at 48 h = =
Number of chromosomal aberrations at 24 h ↑ ↓
Number of SCE at 48 h ↑ ↓
Mitotic index at 24 h and 48 h ↑ ↓
Proliferation index at 48 h ↑ ↓
Cell cycle arrest ↓ ↑
Number of apoptotic cells at 16 h and 24 h ↑ ↓
Chromosomal abnormalities at 100-day culture Absent Present
Table 1. Summary of results obtained in Jurkat p53Arg and p53Pro after drug treatment.
www.nature.com/scientificreports/
8SciEntiFic REPORTS |           (2019) 9:150  | DOI:10.1038/s41598-018-36931-x
to escape from negative regulation by iASPP39. Most of these studies were performed on tumoral cells but Jeong 
et al.38 included also non-tumoral cells with identical results.
Finally, we were able to detect the t(15;17) translocation and del(5)(q33) in Jurkat p53Pro cells, but not in 
Jurkat p53Arg cells, after treatment with doxorubicin or busulfan, respectively, and after a long-term culture. 
These chromosomal abnormalities are likely to be related to DNA breaks that have been repaired aberrantly40. 
Other authors have reported the t(15;17) translocation in patients with t-AML, especially arising after treatment 
with anthracyclines (doxorubicin, epirubicin, or daunorubicin) and/or mitoxantrone41,42. Moreover, happloin-
sufficiency of the RPS14 gene on 5q33 has been implicated in the pathogenesis of MN, even though mutations in 
other genes are needed for the pathogenesis and progression of t-MN43.
Taken together, the results from the present study showed that the p53Arg-expressing cells presented an 
increased rate of DNA damage compared to p53Pro-expressing cells after treatment with the same dose of busul-
fan or doxorubicin. These lesions were probably incompletely or inefficiently repaired and the apoptotic program 
was triggered. As most cells with high levels of DNA damage died, no chromosomal abnormalities were observed 
in Jurkat p53Arg cells. On the other hand, p53Pro-expressing cells had fewer DNA breaks, probably due to cell 
cycle arrest and DNA damage repair. Therefore, these cells were less prone to perform apoptosis. In some of these 
Jurkat p53Pro cells, DNA repair was erroneous, generating chromosomal abnormalities typical of t-MN observed 
after a long-term culture. Figure 6 shows a model of possible mechanisms underlying differences in t-MN risk in 
patients treated with the same doses of chemotherapy and/or radiation according to the ability of individuals to 
undergo apoptosis or to repair DNA lesions more or less efficiently related to the TP53 polymorphism.
In conclusion, the association study presented here showed that the Pro variant of Arg72Pro polymorphism 
at TP53 and the G allele at MDM2 SNP309 had an influence on the t-MN risk. Moreover, we observed in isogenic 
cell lines that the two TP53 polymorphic variants at codon 72 were functionally distinct; they had different effects 
on DNA damage levels and on generation of chromosomal abnormalities after treatment with an alkylating agent 
or a topoisomerase II poison. We suggest that these differences may influence t-MN risk. Previous studies have 
also reported that p53Arg is more efficient in suppressing malignant transformation than p53Pro19,38. Our asso-
ciation analysis indicated that there must be other genes, probably from the p53 pathway, that can be modulating 
the t-MN risk, e.g. MDM2 SNP309. Other p53 pathway proteins that interact with or are under the control of p53 
have been found to contain polymorphisms of potential clinical interest, such as ATM and p21, among others 
(reviewed in44). It will be very important to confirm the effect of p53-pathway polymorphisms on t-MN risk in 
larger series of t-MN patients and their appropriate controls in a near future.
Patients and Methods
Patients. The study comprised 45 patients with t-AML or t-MDS, and a control group of 66 patients (37 males 
and 29 females) that had been diagnosed with acute leukemia, treated with chemotherapy (and in some cases 
with concomitant radiotherapy) and who 5 years or more after treatment had not developed a t-MN. All patients 
were informed about the study and provided their consent. The research was conducted in accordance with the 
Declaration of Helsinki, and it was approved by the Clinical Research Ethics Committee of Vall d’Hebron Hospital 
from Barcelona, Spain and by the Clinical Research Ethics Committee of Jose María Morales Meseguer Hospital 
from Murcia, Spain. Clinico-biological characteristics of t-MN patients are shown in Supplementary Table S1.
DNA isolation and genotyping. DNA was extracted following standard methods described in 
Supplementary Methods. The samples were genotyped for the TP53 Arg72Pro SNP and the MDM2 SNP309 by 
the Polymerase Chain Reaction - Restriction Fragment Length Polymorphism (PCR-RFLP) method, following 
the procedure proposed by45 and46, respectively (Supplementary Methods).
Cell lines. To directly assess the biological effect of the TP53 polymorphism on cells treated with chemother-
apy agents, we established isogenic cell lines expressing p53Arg or p53Pro. Unfortunately, MDM2 null cells are 
not viable and such a model could not be constructed for the MDM2 gene. Details about cell culture, plasmids, 
retroviral production and infection are described in Supplementary Methods.
Immunofluorescence staining and analysis of γ-H2AX foci. To assess the kinetics of γ-H2AX foci 
induction and disappearance following drug treatment, immunostaining of foci and microscopic analysis was 
performed as described in Supplementary Methods.
Figure 6. Hypothetical model of t-MN development after treatment with chemotherapy and/or radiotherapy. 
The capacity of cells to undergo apoptosis or to arrest cell cycle and repair DNA damage more or less 
efficiently can be influenced by genetic polymorphisms in the p53 pathway, for example, the TP53 Arg72Pro 
polymorphism.
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Chromosome breakage assay, SCE assay, and cell proliferation. After drug treatment, we per-
formed chromosome breakage assay and SCE assay as described in Supplementary Methods. Cell proliferation 
was also measured.
Apoptosis assay. Apoptosis was assessed after drug treatment, following manufacturer’s instructions 
(Supplementary Methods).
Fluorescence in situ hybridization (FISH) and PCR. Cell cultures treated with drugs were grown for 
100 days. FISH assay was performed to detect MLL rearrangement, t(15;17) PML-RARA and deletion of chromo-
some 5 or 7. Moreover, DNA was extracted and cells were genotyped for FLT3-ITD and NPM1 mutations by PCR. 
Details are described in Supplementary Methods.
Statistical analysis. Statistical analysis was performed as described in Supplementary Methods.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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